RIGHT HIP, ARTHRITIS DAMAGED; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRITIS (RIGHT HIP, ARTHRITIS DAMAGED) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (Moderate to severe rheumatoid arthritis).   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced ARTHRITIS (RIGHT HIP, ARTHRITIS DAMAGED). At the time of the report, ARTHRITIS (RIGHT HIP, ARTHRITIS DAMAGED) outcome was unknown.            No concomitant medication were provided.  t was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment details were provided.  Company Comment: This spontaneous case concerns a 58-year-old, female patient with history of co-suspect administration of Humira (adalimumab) for Moderate-to-severe Rheumatoid Arthritis and history of co-suspect administration of a booster dose (unspecified dose number) of the mRNA-1273 vaccine, who experienced the unexpected, non-serious AESI of arthritis (arthritis-damaged Right hip). The event occurred unknown number of days after receiving a booster dose (unspecified dose number) of the mRNA-1273 vaccine. Of note, the patient received two booster doses of the mRNA-1273 vaccine. The vaccination dates and the event onset date were not provided, hence, the onset latency could not be assessed. No details were provided regarding symptoms, consultation, diagnostic test/s and treatment. The outcome of the event was unknown at the time of the report. The patient's medical history of Moderate-to-severe Rheumatoid Arthritis remains a confounder. The history of co-suspect administration of Humira (adalimumab) and a booster dose (unspecified dose number) of the mRNA-1273 vaccine also remain as confounders. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 58-year-old, female patient with history of co-suspect administration of Humira (adalimumab) for Moderate-to-severe Rheumatoid Arthritis and history of co-suspect administration of a booster dose (unspecified dose number) of the mRNA-1273 vaccine, who experienced the unexpected, non-serious AESI of arthritis (arthritis-damaged Right hip). The event occurred unknown number of days after receiving a booster dose (unspecified dose number) of the mRNA-1273 vaccine. Of note, the patient received two booster doses of the mRNA-1273 vaccine. The vaccination dates and the event onset date were not provided, hence, the onset latency could not be assessed. No details were provided regarding symptoms, consultation, diagnostic test/s and treatment. The outcome of the event was unknown at the time of the report. The patient's medical history of Moderate-to-severe Rheumatoid Arthritis remains a confounder. The history of co-suspect administration of Humira (adalimumab) and a booster dose (unspecified dose number) of the mRNA-1273 vaccine also remain as confounders. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.